The Review Board for Medicine of the Deutsche Forschungsgemeinschaft (DFG) has appointed Helmholtz Munich scientist Dr. Marcus Conrad as a new member of the DFG’s Hinterzarten Circle on Cancer Research. Marcus Conrad succeeds Prof. Greten from…
More than three percent of the world’s population (around 300 million people) are living with a chronic hepatitis B virus (HBV) infection. Having chronic hepatitis B increases the risk for patients to develop liver failure, liver cancer or cirrhosis…
Helmholtz Munich researcher Kristian Unger, head of Translational Bioinformatics at the Department of Radiation Cytogenetics (ZYTO), together with scientists from the LMU Radiation Clinic and the LMU Medical Physics, has developed the AI method…
What exactly are the molecular interactions between the virus causing COVID-19 and its human host? How might our genetic differences cause different disease courses? And how do still-emerging virus variants differ in their host-virus interactions? To…
Surface molecules EGFR and Integrin beta 4 play a key role in this process
Frequently, cancer patients do not die because of their “initial tumor” in a specific organ. Only when individual cells of the primary tumor transform, migrate or colonize…
At the 9th Immunotherapy of Cancer Conference (ITOC), held September 22 to 24, 2022 in Munich, Helmholtz Munich presented preclinical data showing that PH-762, an INTASYL compound targeting PD-1, increases the frequency of a T cell population…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: